Zach Klaassen· @zklaassen_md · X·· 2 days agoScore70
Body · original
Capi + Abi vs PBO + Abi in PTEN-deficient mHSPC: Updated OS from CAPItello-281 @urotoday #ESMO26
Capi + Abi vs PBO + Abi:
📌mOS: 57.4 mos vs 46.5 mos; HR 0.82, 95%CI 0.68–0.99; p=0.044
📌m-rPFS: 35.5 mos vs 26.0 mos; HR 0.83, 95%CI 0.70–0.99; p=0.033
📌mSSE-FS: 43.8 mos vs 35.9 mos; HR 0.83, 95%CI 0.69–0.99; p=0.044
178 views · 2 likes · 0 reposts · 0 replies
Conference abstracts
Capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC): Updated overall survival (OS) from CAPItello-281
https://esmocongress.esmo.orgSource: Zach Klaassen · x.com